Evaluation of clinical effects of alcomideps

Acoramidis (acoramidis, trade nameAttruby) is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment ofwild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). ATTR-CMIt is a rare and serious heart disease that mainly affects the myocardium, causing abnormal proteins to be deposited in the heart, thereby hardening the heart wall, affecting the normal relaxation and congestion of the left ventricle, and may eventually cause heart failure. There are two main types of the disease: hereditary ATTR-CM (hATTR-CM), caused by mutations in the transthyretin gene Caused by familial genetic characteristics; and wild-type ATTR-CM (wATTR-CM), whose occurrence is not related to genetic mutations.

The clinical efficacy of alcomidex was verified through an international multi-center randomized, double-blind, placebo-controlled trial. The study enrolled 611 adult patients with wild-type or hereditary ATTR-CM (study number NCT03860935) to evaluate the efficacy and safety of alcomidex. The study's primary endpoints include all-cause mortality and cardiovascular-related hospitalizations within 30 months. The results showed that the survival rate of patients treated with acomidex reached 81% at 30 months, which was significantly higher than the 74% of the placebo group. In addition, the rate of cardiovascular-related hospitalizations was significantly lower in the acumideps group, averaging just 0.3 hospitalizations per year compared with 0.6 hospitalizations in the placebo group. These data suggest that alcomidex has a significant effect in reducing mortality and hospitalizations.

In terms of safety, alcomidex was generally well tolerated. The most common adverse reactions include diarrhea and upper abdominal pain, however these gastrointestinal reactions are usually mild and usually resolve without discontinuation of medication. This safety profile makes alcomidex a reliable treatment option for patients with ATTR-CM.

With the pairATTR-CMDue to increased understanding and advances in diagnostic tools, the incidence of this disease continues to increase. The approval of alcomidex provides patients with a new treatment option that is expected to effectively improve prognosis and quality of life. By reducing heart disease-related mortality and hospitalizations, alcomidex offers new hope to patients with ATTR-CM.

Reference link:https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis